| Trial ID: | L0421 |
| Source ID: | NCT03063879
|
| Associated Drug: |
Sofosbuvir 400 Mg And Daclatasvir 60 Mg
|
| Title: |
Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir
|
| Acronym: |
SD-CRF
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hepatitis C, Chronic|Chronic Renal Failure
|
| Interventions: |
DRUG: Sofosbuvir 400 mg and daclatasvir 60 mg
|
| Outcome Measures: |
Primary: Sustained Viral Response (SVR12), Lack of detectable hepatitis C virus in blood 12 weeks after end of treatment, 12 weeks after end of treatment | Secondary: Safety as assessed by adverse drug events, Adverse drug events recorded by direct questioning, From start of treatment to 12 weeks after end of treatment
|
| Sponsor/Collaborators: |
Sponsor: Tehran University of Medical Sciences | Collaborators: Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|Hamadan University of Medical Science
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
95
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2017-04-01
|
| Completion Date: |
2019-02-01
|
| Results First Posted: |
|
| Last Update Posted: |
2019-09-30
|
| Locations: |
Shariati Hospital, Tehran, 14117, Iran, Islamic Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT03063879
|
